Leaping the hurdles in developing regenerative treatments for the intervertebral disc from preclinical to clinical

Abbey A. Thorpe | Frances C. Bach | Marianna A. Tryfonidou | Christine L. Le Maitre | Fackson Mwale | Ashish D. Diwan | Keita Ito

Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands
Department of Surgery, McGill University, Montreal, Canada
Spine Service, Department of Orthopaedic Surgery, St. George & Sutherland Clinical School, University of New South Wales, Sydney, Australia
Orthopaedic Biomechanics Division, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
Department of Orthopedics, University Medical Centre Utrecht, Utrecht, the Netherlands

Correspondence
Ashish D. Diwan, Spine Service, Department of Orthopaedic Surgery, St. George & Sutherland Clinical School, University of New South Wales, Kogarah, Sydney, Australia.
Email: a.diwann@spine-service.org
Keita Ito, Orthopaedic Biomechanics Division, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.
Email: k.ito@tue.nl

Funding information
AOSpine, Grant/Award Number: SRN2011_11; Arthritis Research UK, Grant/Award Number: 21497; Dutch Arthritis Foundation, Grant/Award Number: LLP12LP22; Medical Research Council, Grant/Award Number: MR/P026796/1

Chronic back and neck pain is a prevalent disability, often caused by degeneration of the intervertebral disc. Because current treatments for this condition are less than satisfactory, a great deal of effort is being applied to develop new solutions, including regenerative strategies. However, the path from initial promising idea to clinical use is fraught with many hurdles to overcome. Many of the keys to success are not necessarily linked to science or innovation. Successful translation to clinic will also rely on planning and awareness of the hurdles. It will be essential to plan your entire path to clinic from the outset and to do this with a multidisciplinary team. Take advice early on regulatory aspects and focus on generating the proof required to satisfy regulatory approval. Scientific demonstration and societal benefits are important, but translation cannot occur without involving commercial parties, which are instrumental to support expensive clinical trials. This will only be possible when intellectual property can be protected sufficiently to support a business model. In this manner, commercial, societal, medical, and scientific partners can work together to ultimately improve patient health. Based on literature surveys and experiences of the co-authors, this opinion paper presents this pathway, highlights the most prominent issues and hopefully will aid in your own translational endeavors.

KEYWORDS
Intellectual property, intervertebral disc, low back pain, neck pain, regeneration, translation

1 | DESIGNING FOR SUCCESS

When developing new regenerative therapies for the degenerated intervertebral disc (IVD), a major cause of back and neck pain, it is essential to involve multidisciplinary teams from concept, through translation from bench to bedside, and even clinical application. The involvement of end users, including clinicians and patient groups, in the early stage of development is important to ensure that developed therapies will be applicable in the clinic and address an area of unmet need. End user engagement is also often required when applying for...
ethic permission for use of human tissues and clinical trial applications. Furthermore, engagement with end users is often required during design of research phases for funding, especially within Europe. The (regulatory) pathway to clinic is also important to consider from the outset, attention to appropriate laboratory tests to demonstrate proof of concept and initial toxicity and animal testing. Early considerations of commercialization, patenting and regulatory approvals are necessary to reduce delays to clinical trials and pathways to the clinic. Throughout laboratory and animal testing, good laboratory practice (GLP) or similar is required to support findings, regulatory approvals and patent applications. This includes aspects of good record keeping to laboratory maintenance and quality control. The design of clinical trials, stratification of patients and outcome measure design are all important to ensure that the correct questions are addressed at the appropriate time.

This review aims to map out the important aspects to consider during the development of regenerative therapies for the IVD. Covering the developmental stages for a diverse range of regenerative approaches including: gene, cell, biological factors, and biomaterial approaches to repair and regenerate the IVD, as a potential treatment for chronic back and neck pain.

2 | BENCH SIDE TESTING: IN VITRO AND EX VIVO TESTING

The first stage in developing a new regenerative therapy for the IVD is testing in vitro, often in mammalian cell culture. This stage is used to perform initial proof of principle studies and fundamental cellular toxicology (viability) studies on relevant cell types. Important aspects to consider during the design of in vitro and ex vivo testing includes: species, sources of cells and tissues, and culture conditions. The specific question being addressed and stage within the developmental pathway will require different levels of complexity (Figure 1).

2.1 | Species and cell/tissue source

The choice of cell source is an important question. It is well known that species-specific responses can be observed and as such, caution must be applied when using nonhuman cells in initial proof of principle testing. These differences could arise from differential species-dependent expression of proteins and receptors, cell types isolated from tissues (eg, notochordal cells), or the disease status of the tissues. In view of the challenges in accessing human cells, the majority of animal cells utilized in initial experimental studies are from normal young adult animals, which do not represent the cellular phenotype seen within the degenerated (human) IVD, which are senescent and exhibit a catabolic phenotype which has implications on regenerative therapies. Over the last 10 years, there has been increased research on human cell sources with approximately 50% of studies culturing IVD cells or cells for regeneration of the IVD sourced from human (Figure 2A,C). Accessibility to human tissues is more complex for tissue explant or organ culture studies with the majority of these utilizing animal tissues (Figure 2B), especially cow tails, due to their ease of access and similarity in cell type and structure to human discs. Similarities between animal and human disc tissues have been reviewed elsewhere. The utilization of animal tissues can be useful for initial tests and studies have attempted to mimic the degenerate disc within such systems (see below). However, no animal tissue represents the human situation directly. Therefore, human tissues should be utilized wherever possible, which also enables patient variation to be determined. Prior to translation to animal testing, it is also essential to confirm results in vitro within the species of choice for in vivo experimentation to ensure these cell types respond in the same way as human cells prior to animal model selection, as indicated recently, for example, by species-specific responses to Link-N.

2.2 | Culture systems

Two-dimensional (monolayer) culture of nucleus pulposus (NP) cells is well known to lead to changes in cellular phenotype, characterized by rapid de-differentiation within the first passage, for example, loss of normal matrix synthesis (collagen type II and aggregan) and gain of collagen type I. Moreover, it acts as an oversimplification of the cellular environment, lacking cell-extracellular matrix (ECM) interactions. Two-dimensional (2D) culture systems for IVD studies are widely used (Figure 3A). While 2D culture has its use, particularly in initial cellular toxicology studies and preliminary proof of concept studies, it is difficult to translate results from 2D culture directly to the in vivo environment. Three-dimensional culture systems such as pellet or alginate have been shown to restore the phenotype (with appropriate expression of IVD matrix molecules) of native NP cells and collagen scaffolds for annulus fibrosus (AF), thus, are a useful model to study effects of gene therapy and biological factors. However, these systems are often limited to single cell types and with the exception of newly deposited matrix do not recapitulate the complexity of cellular and extracellular matrix components and interactions.
thereof, which exist in vivo. The IVD regeneration field would benefit from defining a standard culture system such as alginate for NP and collagen for AF cells and its conditions (Table 1) that would be used worldwide and as such enable comparison of efficacy results. However, the defined “gold standard” will still need adjustments depending on the clinical questions addressed, as conditions in the IVD differ depending on age, spinal level, health state and underlying disease process.

Until early in the 21st century, culture of IVD tissue explants, especially NP tissue explants, were hampered by tissue swelling, loss of extracellular matrix, cellular phenotype and viability. However, a number of culture systems are now available which can maintain tissue explants of animal and human tissue in culture for prolonged periods of time. These systems either constrain tissue volume,3,27,28 culture tissue in raised osmotic pressures,29 or under compressive loading,30 which prevents tissue swelling, maintains tissue architecture and cellular phenotype. These systems are particularly useful as human tissue obtained from surgery can be utilized as small pieces of intact tissue and can be maintained in culture. Such systems have been employed to excellent effect to study proof of principle studies on regenerative approaches including biological,31,32 cellular33–35, and injectable hydrogel systems.36 These studies can provide useful initial data on local tissue responses, integration and delivery to tissues, which are essential in the pathway to clinic.

However, NP explants fail to model the interactions of different cell types within the disc and nutritional diffusion. Although this can be simulated to a certain extent by adjusting the nutrient supply in the media, this does not mimic the gradient seen in a whole IVD. Thus, a number of organ culture bioreactors have been developed which can maintain whole discs: mainly mouse, rabbit, sheep, cow, and goat discs. Recently, a long-term IVD organ culture model that retains the vertebral bone system was developed.6 This model is useful for testing potential drugs on disc repair37 and is based on the bovine IVD. To study repair, IVDs are maintained in organ culture and degradation is induced by injection with trypsin. The whole organ culture system used for the bovine work is to some extent applicable to human IVDs, but in this case degeneration is not truly reflective of the human IVD. A number of systems have recently been developed which can maintain whole cadaveric human discs, which can allow investigations in naturally degenerate tissues.38–40 These systems have been reviewed in a number of excellent reviews.41,42

2.3 | Culture conditions

The native IVD in vivo is a hostile environment, characterized by low oxygen tension, low nutrition, high osmolality, low pH and exists under dynamic load43,44 (Table 1). Yet the majority of in vitro studies are performed in nutrient-rich culture media, most commonly Dulbecco’s...
Modified Eagle Medium (DMEM) or DMEM/F12 consisting of high glucose concentrations, at neutral pH (7.4), low osmolality (~350 mOsm/kg), and under static culture conditions at 21% O2. The NP experiences mostly hydrostatic pressure, as high as 2.5 MPa, whereas the AF is under complex loading leading to direction-dependent tensile, compression and shear stresses. The magnitude, duration and frequency of tissue loading, and deformation varies over a diurnal cycle.

Culture conditions are also essential to consider during expansion of cells for biobanking of IVD cells for regenerative approaches. Expansion conditions, including passage number, oxygen tension, supplements, and osmolality have been shown to influence the cell phenotype and as such influence the regenerative capacity and differentiation of mesenchymal stromal cells and NP cells. These conditions can be tuned, either to achieve optimal regenerative performance or to achieve an NP phenotype that resembles better the NP cells present within a degenerative niche.

During testing of regenerative approaches, systems should be tested within conditions which mimic the native IVD environment (Table 1). However, key factors preventing many researchers from modulating culture conditions are the comparison to previously published data and facilities that are available. Some studies are indeed starting to modulate these conditions within in vitro culture studies (Figure 3B). A key feature, however, which currently hampers in vitro culture modifications is accurate determination of actual levels seen in vivo. Furthermore, these conditions are known to change during degeneration, but levels will vary between patients and across regions within the IVD, and these measures are very difficult to determine in vivo and often depend on computer modeling to provide suggested conditions.
TABLE 1  Recommended culture conditions to mimic the normal and degenerated intervertebral disc (IVD) environment

|                          | Normal IVD | Degenerate IVD |
|--------------------------|------------|----------------|
| Oxygen tension (%)       | 1-5        | 1-5            |
| Glucose concentration (nM/mm²) | 0.94-4     | 0.94-4         |
| Osmolality (mOsm/kg)     | 400-500    | 350            |
| pH                       | 7.0-7.2    | 6.5-7.1        |
| Loaded environment       | Dynamic    | Dynamic Load   |

Catabolic factors²⁵,²⁶ Cytokines (particularly IL-1; 100 pg/mL), Ca²⁺ (2.5-5 mM), or use of naturally degenerate cells/tissue within 3D culture, explants and organ cultures

Note that for proper mimicking the degenerative environment in 3D hydrogel culture low density of cells should be employed; for explant and organ culture diffusion of oxygen and glucose into the disc should be considered and thus higher culture concentrations may be required to result in these internal concentrations. However, in order to gain a more educated understanding of how potential regenerative therapies will behave within the complex environment of the degenerated human IVD, in vitro and ex vivo culture systems must evolve to recapitulate the conditions seen within the degenerated IVD.

3 | MODELING THE DEGENERATIVE NICHE IN VITRO

The degenerated IVD is a hostile environment for cells with further decrease in nutrients and pH and altered osmolarity compared to normal discs, which was recently reviewed by Sakai and Anderson.⁴³ The degenerated niche also contains abundant catabolic cytokines, degradative enzymes, matrix fragments increased levels of free calcium (Ca²⁺),⁶ neurotrophic and angiogenic factors, which together could alter the behavior of any proposed regenerative therapy.⁴⁸ For therapies which rely on the native cells of the IVD, these become senescent,¹³ alter phenotype, and undergo apoptosis, which results in an altered and/or reduced cell source available to respond to potential gene and biological treatments.⁴⁸ While newly implanted cell sources may not survive and/or differentiate into the correct NP cell phenotype within the catabolic environment of the degenerate disc.⁴⁹ Hence, it is important to assess any potential regenerative therapy within an environment which mimics the degenerate niche as much as possible (Table 1) prior to progression to clinical trials. ex vivo tissue explant and organ culture systems have in part begun to re-create this niche with various degrees of success. Methods to mimic the changes observed in human IVD degeneration include enzymatic NP digestion,⁵⁰ surgical methods to create AF injury,⁵¹ and overloading (by magnitude, duration, and frequency).⁵² However, these systems can only replicate some morpho-histo-pathological and cellular changes and it is unknown how closely they mimic/induce in vivo degenerative mechanisms. To date, the best ex vivo model systems available are those based on human degenerative IVD tissue/organs, but even these do not fully recapitulate the full in vivo environment as they are decoupled from systemic interactions, for example, immune, nervous, and endocrine systems.

4 | PRECLINICAL ANIMAL MODELS

When promising (regenerative) treatment candidates have been established in vitro and/or in ex vivo tissue/organ cultures mimicking the degenerative disc niche, the next step would be to test these candidates in clinically relevant animal models for safety and efficacy prior to starting human clinical trials. To generate an overview of the types of efficacy outcome measures previously used, a literature search for papers published over the last 20 years on “regenerative treatments for the IVD in animal models” was performed. A total of 112 papers were reviewed and the outcome measures appeared to vary considerably between the different types of assessment (ie, histological, macroscopic, radiological, biochemical, mechanical, and pain assessment; Figure 4A,B). It is well known that IVD degeneration is a complex disease with cellular and biochemical matrix changes.¹²,⁵⁷,⁵⁸ Therefore, the assessment of histological and biochemical outcome measures is essential to fully evaluate the native cell response and matrix regeneration capacity of any treatment strategy. Despite this, histological, biochemical and/or radiological changes indicative of degeneration can be found in patients in the absence of pain, demonstrating that the two do not always correlate.⁵⁹-⁶¹ Therefore, histological, biochemical and/or radiological improvements observed in animal models may not necessarily translate clinically into a reduction in disability and for this reason should not be used alone to indicate therapeutic success.

From a clinical point of view, the ultimate aim of any treatment developed for neck and back pain is to alleviate pain and restore the biomechanical function of the IVD. Interestingly, from the 112 papers reviewed, only 4% of these papers performed some kind of biomechanical assessment to determine the success of the therapy under investigation, and to the authors knowledge none of the papers reviewed had assessed pain as an outcome measure following administration of a regenerative therapy (Figure 4). This is likely due to the fact that standardized methods to assess biomechanical function and pain in animal models are less well defined. Furthermore, it is a common practice in translational studies to employ more than one levels within in each animal in order to reduce the number of animals needed in an experiment (3Rs principle: reduction, replacement, refinement). This limits the ability to assess pain properly. As such, once a promising treatment candidate has been encountered in
studies with more than one spinal level injected with a different treatment, it would be recommended to perform an in vivo study on this treatment candidate injected at only one spinal level, enabling pain assessment.

Suitable methods to assess pain in animal models is still in its research infancy; for those that do exist, it is not clear whether these methods will relate to human neck and back pain, since the source of IVD-related pain in humans is not always defined. A number of preclinical small animal models that mimic specific aspects that contribute to low back pain (LBP) has been recently reviewed by Shi et al. Pain measurements in large animal models are primarily qualitative and deduced from objective gait analysis that does not allow for the exact (spinal) localization. Specificity in the case of dog patients with chronic back pain employed as a model for humans within the concept of “One Medicine,” owners can fill in questionnaires regarding pain assessment aspects and inherent impairment of mobility as would humans entering a clinical trial. Despite the difficulties, when evaluating the success of any potential therapy in animal models, it is recommended that some measure of biomechanical function and pain assessment, appropriate to the selected animal model, is performed. These outcome measures should be performed in combination with histological, biochemical and/or radiological outcome measures to evaluate the native IVD cell response, including production of catabolic/inflammatory factors, repair of matrix components and restoration of disc height. All outcomes should ideally be determined blindly and objectively, for example, by using quantitative scoring systems. This will improve knowledge concerning the efficacy of the therapeutic and may improve the translation of clinical findings within animal models to those found in humans. In this way, the chance of failure of the treatment candidate in human clinical trials would be reduced and translational success would be improved.

Commonly used experimental animal models for IVD degeneration include mice, rats, rabbits, dogs, sheep, goats, and more recently, alpacas have been employed. Each animal model has distinct advantages and disadvantages, and therefore the choice of the animal model depends on the research question posed. It is important to note that no animal model can reproduce the exact nutritional status, biology, anatomy, and biomechanics of the human spine. Animal models differ considerably; there are even pronounced differences between animal breeds. It is evident that the difference in clinical representation of IVD-related disease may strongly be related to the genetic background of the breeds (reviewed for dogs). Similarly, also in humans, genetics play an important role as there have been “risk-genes” identified in this sense. Although several predisposing genes have been reported (eg, aggrecan, collagen type I and XI, matrix metalloproteinase-2, -3 and -9, cartilage intermediate layer protein, Interleukin-1 and -6), only the association of vitamin D receptor (VDR) and collagen type IX (COL9A2) with IVD disease has been verified in different ethnic populations. To our knowledge, no research has yet been performed on the IVD of VDR null or vitamin D-deficient animals. Collagen type IX deficient mice, show early developmental, structural, and biomechanical alterations in their vertebral bodies and IVDs, causing severe degenerative changes in the aging spine. Most identified genes associated with LBP due to IVD degeneration code for proteins affecting ECM integrity, responsible for mechanical properties of the IVD. Thus far, animal studies on the genetics of IVD disease use mice. Although far less well researched, also in larger animal models employed for in vivo studies, genetics can play an important role. Therefore, researchers need to consider this when choosing a suitable animal model.

Differences in IVDs between human and animal species include anatomical (size, shape), biomechanical, biochemical, aging/degeneration, nutritional, cellular, and loading variations as reviewed by Alini et al. The difference in IVD size affects the type and number of readout parameters that can be measured: small IVDs cannot be used to evaluate multiple parameters and assay detection limits coincide with small samples. Also, limitations in relevant volume of therapeutics relative to tissue constructs are encountered. Although for large animal models this is not a specific issue, safe injection volumes and pressure should be determined to avoid injection-induced accelerated degeneration. In this respect, IVD organ cultures are useful for injection volume and extrusion testing before animal models are employed.
By using this approach, previous studies have demonstrated that no adverse effects were observed due to the intradiscal injections themselves, indicating that small volumes can be safely injected (rat: 1.0–1.8 μL; rabbit: 10–20 μL; dog: 40–50 μL; sheep: 0.2–1.0 mL). We recommend injecting these IVD treatments only through the AF. Recent work has shown that the transpedicular approach, proposed as alternative delivery route for IVD regeneration, induced severe damage to the end plates and may lead to neurological impairment and leakage of injected material.

Besides size, the second difference between animal models is that in most animals, degeneration needs to be induced, since this is not a spontaneously occurring phenomenon. Exceptions are the sand rat, and the dog, in which IVD degeneration occurs spontaneously. In most animals, IVD degeneration needs to be induced, since this is not a spontaneously occurring phenomenon. Exceptions are the sand rat and the dog, in which IVD degeneration occurs spontaneously. Recent work has shown that the transpedicular approach, proposed as alternative delivery route for IVD regeneration, induced severe damage to the end plates and may lead to neurological impairment and leakage of injected material.

The third difference between species is the main cell type in the NP. Humans lose their notochordal cells (NCs) during childhood, whereas aging mice, (sand) rats, rabbits, and nonchondrodystrophic (NCD) dogs typically still have NCs in their NP. In contrast, chondrodystrophic (CD) dogs and goats lose their NCs early in life and therefore more closely resemble humans in this respect. Noteworthy, since in several animal species the main NP cell type changes with aging, the age of the experimental animals should be chosen cautiously.

In addition to interspecies differences, all common animal models are quadrupeds. The biomechanical forces exerted on the human IVD are often thought to be uniquely determined by the predominantly upright stature and bipedal locomotion of humans, and are therefore thought to be different to those found within in quadrupedal animal models. However, because of its segmental unstable nature, all spines rely on considerable tensile forces in intersegmental muscles (active) and ligaments (passive) to generate compressive loading on the anterior spinal column for sufficient stabilization. In quadrupeds, these anterior column compressive forces may in fact be higher than those in humans as demonstrated by the higher degree of longitudinal vertebral trabecular alignment and denser trabecular bone. Of course, in addition to compressive loads, spinal segments must rotate in three degrees-of-freedom, and it is understandable to imagine that humans may require different motions from their spine than quadrupeds. However, when comparing the passive resistance to bending, Wilke et al found that the range-of-motion of sheep spinal segments for all load directions was qualitatively similar to that of humans. Nevertheless, when (regenerative) treatment candidates are tested in animal models in vivo, biomechanical testing in comparison to proper controls is recommended.

TABLE 2 Recommendations for the use of in vivo animal models

| Cell type (CLC) in NP | Mouse | Rat | Rabbit | Sheep | Goat | Alpaca | CD dog | NCD dog |
|----------------------|-------|-----|--------|-------|------|--------|--------|---------|
| IVD size             | −     | −   | −      | ++    | ++   | ND     | ++     | −       |
| Spontaneous IVD degeneration | −     | −   | −      | −     | −    | −      | ++*    | ++*     |
| Useful for fundamental/safety studies | ++    | ++  | ++      | −     | −    | −      | −      | −       |
| Useful for translational/efficacy studies | (−)  | (−) | (−)    | +     | +    | +      | ++     | ++*     |
| Expenses for animal experiments | ++    | ++  | ++      | +     | +    | −      | −      | −       |

Abbreviations: CD, chondrodystrophic; CLC, chondrocyte-like NP cell; NP, nucleus pulposus; IVD, intervertebral disc; NCD, nonchondrodystrophic. ++: Best suitable animal model for this specific purpose. +: Suitable animal model for this specific purpose. −: Less suitable animal model for this specific purpose. (−): Although the authors consider these species less suitable for this purpose, recent clinical trials (efficacy studies) did not require large animal studies. ND: not determined. +*: CD dog breeds typically develop IVD disease at relatively young age. NCD dog breeds can also develop IVD disease, but at an older age, mostly due to trauma or “wear and tear”. In the other species, IVD degeneration needs to be induced artificially.
health for new medical solutions, advantageous for humans as well as animals. An important issue of translating treatment strategies into preclinical animal models is the ethics of placebo treatment. Evidence-based placebo treatment increases the scientific validity, but can in the case of an intradiscal sham injection pose risks and/or can lead to reluctance by the owners of the animals. Offering the option to provide the treatment to the patients that had previously received the placebo may increase the number of study participants.

A downside of using large animal models are the ethics and high costs (purchase and housing, multiple costly outcome parameters). Altogether, this often leads to the use of a minimal number of large animals included, impairing the power of the study. Furthermore, an issue concerning all species is the absence of histological scoring systems. To our knowledge, this has only been developed for mice and dogs. In terms of imaging, large animal models have rather similar possibilities as humans with LBP: radiography, fluoroscopy, discography, computer tomography (CT), and magnetic resonance imaging (MRI). However, there are some drawbacks. For instance, quantitative MRI (eg, T1rho and T2 mapping) has been validated for human IVD degeneration, but not for animals. Therefore, this needs to be validated for other species, as well as how the spinal phenotypes present in animal models relate to human pathology to improve translation. Another major concern regarding MRI analysis is that there is a need for validation of regenerative process, since quantitative MRI has specifically been validated for IVD degeneration, but not for regeneration, which does not necessarily follow an identical reverse process. To this end, the recently identified correlation between IVD degeneration, modic changes and back pain indicates that in animal models too these entities need to be explored and properly characterized to fully cover the whole spectrum of spine pathology related to IVD degeneration. Lastly, long-term animal studies are lacking, but must be performed to demonstrate long-term safety and efficacy in clinically relevant animal models and detect pathological features that only develop after a long time period, such as tumorgenicity, before treatments are translated to human clinical trials. Regardless the approach, even if efficacy is demonstrated in a large animal model, it does not necessarily guarantee efficacy in the human patient. Considering the most recent developments regarding regulation and ethics concerning animal modeling, further developments in the preclinical track need to focus on implementation of the 3Rs principles, where replacement and considerable reduction of animal experiments needs to be achieved with sophisticated alternatives employing bioreactor technology mimicking the biology and biomechanics of the degenerative disc niche.

5 | REGULATION

Regulatory pathways for the Food and Drug Administration (FDA), and Medicines and Healthcare products Regulatory Agency approval, will depend on the therapeutic under investigation and whether it is defined as a drug, biologic or device. When considering the well-defined regulatory pathways for drugs, it is estimated that the average length of time from discovery to clinical application is approximately 12 to 15 years with an estimated cost of $800 million. In contrast, the regulatory pathways for biological therapeutic approaches are often more complex and time consuming. The FDA have established that biological drugs include blood-derived products, vaccines, in vivo diagnostic allogenic products, immunoglobulin products, protein products and products containing cells or microorganisms. Given the unique nature of biological therapeutics, the preclinical tests performed to evaluate the safety, purity, potency and efficacy of the therapeutic will often be specific to the biological therapeutic under investigation. It is therefore recommended that researchers have contact with their local regulatory authorities early on in the preclinical experimental design process to ensure that the necessary experiments are being performed in line with the requirements for an IND application and premarket approval (biologics license application). Consideration, early on during preclinical investigations, should also be given to the manufacturing processes of the therapeutic. In comparison to well-characterized synthetic small molecule drugs, regulatory authorities will often require additional clinical studies to demonstrate the identity, safety, purity, potency, and efficacy of the biologic following manufacturing processes.

6 | CLINICAL TRIAL DESIGN

Translating a potential product with great preclinical data to clinical reality, that is, from the bench to bedside, requires numerous steps. For a therapeutic agent that will be injected into the IVD under image guidance as a single dose, the pathway will be that for a new drug application, biological agent, medical device, or advanced therapy medical product. While the regulatory nuances can differ from one regime to another, some principles remain the same. Here, we describe numerous steps, documents, principles, and three-lettered acronyms involved in completing the clinical translational work for regenerative therapies for the IVD (Figure 5). On identification of a suitable target, completion of proof of concept work, assuring a high quality Chemical and Manufacturing Control when needed,
confirmation of preclinical toxicological work on the final product that will be used in clinical trials, with or without the requirement that the final product is made using Good Manufacturing Practices. A team with experience in early commercialization or clinical translation must be involved.

An Investigator Brochure is the first step. This document summarizes the history of the product development, characterization of the active pharmacological/biological ingredient, medical device or ATMP, mechanism of actions, all preclinical work and toxicological profiles (Table 3: list of toxicological work) and any functional pain studies performed. An indication for use (IFU) has to be stated clearly. It is important that all preclinical and proof of concept work is consistent and appropriate with this IFU.

The IFU becomes the basis of developing a Clinical Trial Protocol (CTP). This activity requires the input of clinicians who understand the Good Clinical Practice (GCP) for Trials and the Helsinki declaration. Trials are to be conducted on sites that are GCP compliant, as determined by the clinical trial sponsor from the initiation to completion of the study. The key elements of the CTP are: clear identification of the inclusion and exclusion criteria, clearly defined outcome measures and validation of the tools for clinical outcomes, a time table for what will be measured when, establishment of a Data Safety & Monitoring Board that can stop a trial in the event of a Serious Adverse Event, and a detailed Subject Information Sheet/Document. For patients undergoing a LBP study, each clinical trial protocol will be different, however, the minimum expectation for outcome tools will include a score for back pain, a disability measuring tool and a quality of life instrument (Table 4). Patient Reported Outcome Measures while generally accepted, are being questioned now in favor of subjectively

**FIGURE 5** A road map of the pathway to clinical success of a potential intradiscal therapeutic agent. While each stage has hurdles of its own, comfort with acronyms and language around various steps and documentations needed is a good first step in resolving those hurdles. All activities may cumulatively take anywhere between 12 to 15 years. CMC, chemical and manufacturing control; GMP, good manufacturing practices; IND, investigational new drug; IFU, indication for use; IRB, institutional review board or ethics committees

**TABLE 3** Toxicological and analytical work that may be required for investigational new drug (IND) application

| Type of study                                | Model                      |
|----------------------------------------------|----------------------------|
| Pharmacokinetics                            |                            |
| Intramuscular pharmacokinetics               | Rat                        |
| Six-month single dose safety study          | Rat                        |
| Toxicology                                  |                            |
| Pyrogen test                                 | Rabbit                     |
| CNS safety profile                          | Rodents                    |
| Blood fibrinogen consumption test           | Human blood in vitro       |
| platelet activation, complement activation test, hemolytic activity test | |
| Cardiovascular and pulmonary safety         | Rodents                    |
| Intramuscular bone or tissue induction      | Rodents                    |
| Effects on cell phenotype, metabolic activity, binding/affinity studies | In vitro depending on active ingredient (described above in preclinical studies) |
| Bioanalytical                               |                            |
| Dosing solution/delivery agent method development and validation | In vitro |
| Plasma assay development and validation     | In vitro                   |

The principles of understanding the pharmacodynamics and pharmacokinetics along with toxicological profile of the agent while being able to quantify the drug, its metabolite have to be demonstrated for other advanced therapies (including cell therapies), the toxicological and analytical work required is derived from the principles for drugs as listed.
TABLE 4 Minimum outcome measures for a low back pain study

| Minimum outcome measures | Example of scoring system/measurement |
|--------------------------|--------------------------------------|
| Pain                     | VAS, NRS                              |
| Disability               | ODI, Roland Morris                    |
| Quality of life          | SF36, EQ5                             |
| Radiological             | DHI, MRI scans (if possible T1rho mapping) |

Abbreviations: DHI, disc height index; EQ5, European quality of life 5 questions; MRI, magnetic resonance imaging; NRS, numeric rating scale; ODI, Oswestry disability index; SF36, 36-item short form health survey; VAS, visual analog scale.

A clinical trial protocol has to consist of subjective (patient reported) and objective (investigator determined) outcome tools.

Radiological outcomes will be expected too, where the minimum will be a disc height measurement on a standing lateral X-ray in neutral position. While (quantitative) MRI provides information on the degenerative stage of the IVD at the initiation of the study, the role of clinical MRI as outcome measures are uncertain and may not serve practical utility during a clinical trial. However, including MRI as a secondary read out parameter will assist follow up of the degenerative state of the treated disc and demonstrate the development or lack of additional pathologies, for example, modic changes. The role of endplate changes cannot be discounted but there is lack of consensus among researchers and clinicians as to their importance or predictive role in LBP. T1rho MRI mapping has been recently proposed as a marker for painful discs. However, lack of extensive clinical use and inadequate extensive validation of this imaging modality requires more work. Secondary outcome measures may include use of supplementary therapy and ability to work. Adverse events (AEs) are monitored throughout the trial and serious adverse events would include death, paralysis, infection and un-remittent exacerbation of pain.

In the context of the United States Food and Drug Authority, an intradiscal therapeutic agent will be assessed as a drug product by the Center for Drugs Research and Development (Figure 6). It is expected that a New Drug Application (NDA) has to be lodged, towards which the trial has to be conducted under an IND. This will require a safety combined with dosage study as a Phase II clinical trial followed by an efficacy Phase III trial, where a double blinded randomization (patient and physicians including care team do not know who received the drug till final data analysis) using a placebo arm to compare the experimental therapeutic agent. Since no objective outcome measures are available, the subjectivity of clinical symptoms is high in patients with IVD disease. Therefore, determining the effects of placebo treatment (eg, sham intradiscal injection) is preferable for scientific validity. Placebo treatment creates an ethical dilemma between maximizing the scientific value of the study and minimizing risk to participants. The ethical acceptability of placebo treatment is therefore mainly affected by the associated procedure risks for the relatively healthy patients with IVD disease, which often do not suffer from any comorbidities. In both Phase II and III trials, data for safety has to be compulsorily obtained and preliminary efficacy can be tested in Phase II. Whether a regulatory agency will accept another expedient clinical trial model like a single arm study without a control will be dependent on the ability of the sponsor to demonstrate compelling socio-economic reasons or “orphan-disease” status for their indication. Furthermore, varying dose studies, multiple disc levels treatment or a repeat injection study should best be addressed after market approval for the drug for one level and one dose; as incorporating these questions in a regulatory study will not only make the trial unwieldy, but also add un-sustainable cost and time. Such further studies can be investigator-initiated with or without regulatory oversight.

A complete statistical plan and data management plan are essential. The trial has to be listed at clinicaltrials.gov. Data from the IND (in case the therapy is a protein or a drug) has to be submitted for a NDA which requires multiple and stringent regulatory reviews that may include panels consisting of lay persons and experts. Other regulatory regimes have similar or slight variations. In case a scaffold is classified as a device an Investigational Device Exemption (IDE) study submission followed by a Pre Market Approval (PMA) will be needed. The IDE may require a pilot, a pivotal or a comprehensive study based on what is being evaluated and in consultation with the FDA utilizing their pre-submission process. More importantly, regulatory harmonization between various countries can help to speed up regulatory approval processes.
| Active agent                              | Sponsor name                                      | Clinical trial number/IND/reference                                                                 | Status/outcome                                                                 |
|------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Allogeneic discogenic cells              | DiscGenics Inc.                                   | NCT03347708                                                                                     | FDA allowance of IND to commence clinical study (October 2017). Currently recruiting. |
| Autologous disc cells                    | TETEC; NOVOCART                                   | NCT01640457                                                                                     | Phase I/II (n = 120); ongoing                                                                 |
| Allogeneic juvenile chondrocytes         | NuQu, ISTO Technologies Inc.                      | NCT01771471                                                                                     | Phase II enrolment completed (n = 44); final results expected in 2014. Current status: terminated (change in clinical strategy) |
| Allogeneic mesenchymal precursor cells   | Mesoblast Ltd.                                    | • NCT01290367                                                                                   | • Phase II (n = 100): significantly greater pain reduction (VAS, ODI, opioid use), but large placebo effect. IVD MRI changes are missing. |
|                                         |                                                   | • NCT02412735                                                                                   | • Phase III (n = 360): ongoing. Cells with hyaluronic acid vs placebo                                                              |
| Allogeneic bone marrow-derived mesenchymal stromal cells | Red de Terapia Celular                           | NCT01860417                                                                                     | Phase II (n = 25): results not published                                                                                           |
| Allogeneic bone marrow-derived mesenchymal stromal cells | Noriega et al (2017)140                          |                                                                                                 | Phase I (n = 24) showed safety. 40% responders                                                                                     |
| Autologous adipose-derived mesenchymal stromal cells | Kumar et al (2017)141                             |                                                                                                 | Phase I (n = 10) showed safety. VAS and ODI scores significantly improved                                                          |
| Autologous bone marrow concentrate cells | Pettine et al (2015)142                           | Pilot study (n = 26): ODI and VAS scores reduced. Eight patients improved by one modified Pfirrmann grade |
| Placental tissue extract (BioDGensis)    | Semmes-Murphey Foundation                         | NCT02379689                                                                                     | Phase I/II (n = 30): results unknown                                                                                               |
| Recombinant human bone morphogenetic protein-7 (rhBMP-7) | Stryker; Olympus Biotech                          | Imai et al (2007)85,90                                                                            | • Product available in Australia, Canada, Germany, Italy and Spain for bone formation                                             |
|                                         |                                                   |                                                                                                 | • Development for intradiscal injection did not progress beyond Phase II trials. In line with this, later in vivo experimental work demonstrated the absence of a regenerative effect and possible adverse effects in Beagle dogs |
| Recombinant human growth and differentiation factor-5 (rhGDF-5) | DePuy Synthesis Spine (J&J subsidiary)            | • NCT01158924 (n = 40)                                                                            | All studies completed Phase II; inconclusive study results                                                                         |
|                                         |                                                   | • NCT00813813 (n = 32)                                                                            |                                                                                                                                     |
|                                         |                                                   | • NCT01128337 (n = 31)                                                                            |                                                                                                                                     |
|                                         |                                                   | • NCT01124006 (n = 24)                                                                            |                                                                                                                                     |
| Fibrin                                   | BIOSTAT BIOLOGX                                   | • NCT00693784 (pilot study); Yin et al (2014)143                                                  | • Pilot study (n = 15) showed safety                                                                                               |
|                                         |                                                   | • NCT01018116 (Phase III)                                                                         | • Phase III (n = 220) withdrawn because of lack of efficacy                                                                      |
|                                         |                                                   |                                                                                                 | • Product on market for other indications including surgical hemostasis                                                           |
| Methylene Blue                           |                                                   | • Peng et al (2010)                                                                               | • Phase I (n = 40): preliminary                                                                                                   |
|                                         |                                                   | • Levi et al (2014)                                                                               | • Peng et al (2010) (n = 136): reduction in pain, ODI, improved satisfaction rate                                               |
|                                         |                                                   | • Kallewaard et al (2016)                                                                         | • Levi et al (2014) (n = 16): no clinical success                                                                                 |
|                                         |                                                   | • NTR2547 (NL)144                                                                                | • Kallewaard et al (2016) (n = 15): 40% positive responders                                                                         |
| IL-6R mAB                                | Sainoh et al (2017)148                            | Tocilizumab, Actemra, and RoActemra available on market. Efficacy for back pain not known.        |                                                                                                                                     |
| Platelet-rich plasma                     |                                                   | • NCT02983747 (Phase II)                                                                          | Phase II (n = 112) completed, results are awaited.                                                                                   |
|                                         |                                                   | • Monfett et al (2016) (literature review)                                                        | • Tuakli-Wosornu et al (2016) (n = 47): improvements in FRI, NRS, and patient satisfaction                                          |
|                                         |                                                   | • Tuakli-Wosornu et al (2016)                                                                      | • Levi et al (2016) (n = 22): after 6 months success rate of 47% (eg, 50% improvement in VAS and 30% decrease in ODI) |
|                                         |                                                   | • Levi et al (2016)                                                                               | • Akeda et al (2017)149–152: results unknown                                                                                     |
|                                         |                                                   | • Akeda et al (2017)                                                                              | • Akeda et al (2017) (n = 14): VAS score improved, MRI T2 values not changed                                                      |
| Glucocorticoid                           | Hydro-cortancyl (Prednisone-lone)                  | • NCT00804531                                                                                   | Phase IV (n = 137): efficacy not clear                                                                                             |
|                                         |                                                   | • Nguyen et al (2017)153                                                                          |                                                                                                                                     |
| YH14618                                  | Yuhan Corporation                                 | NCT02320019                                                                                     | • Peptide derived from biglycan, binds to TGFβ1 and downregulates Smad1/5/8 signaling                                           |
|                                         |                                                   |                                                                                                 | • Phase II (n = 326) completed, results awaited                                                                                     |
| AMG0103                                  | AnGes, Inc.                                       | NCT03263611                                                                                     | • Nuclear factor-κB Decoy oligodeoxyxucleotide                                                                                  |
TABLE 5 (Continued)

Intradiscal therapies under an IND or with a clinical trial number or published

| Active agent | Sponsor name | Clinical trial number/IND/reference | Status/outcome |
|--------------|--------------|-------------------------------------|----------------|
| SM04690      | Samumed LLC  | NCT03246399                        | • Phase I (n = 24); recruiting |

Abbreviations: FDA, Food and Drug Administration; FRI, functional rating index; IL-6 mAB, interleukin-6 monoclonal antibody; IND, investigational new drug; IVD, intervertebral disc; ODI, Oswestry disability index; OUS, outside of the United States; MRI, magnetic resonance imaging; NRS, numeric rating scale for pain; VAS, visual analog scale.

approvals. Intradiscal therapies that have undergone or are undergoing clinical trials are provided in Table 5. As one can deduce from the table, there are several developed molecular or biological therapies that have failed thus far to show efficacy, while other remain in the race. The challenges and hurdles that still remain may have to do with not only the harsh environment of the degenerative disc. Patient stratification is an important consideration for achieving desirable outcomes. Appropriate trials and identifying which patients will benefit from which treatments is essential to determine the commissioning/approvals of treatment regimes.

Funding the intradiscal treatment, will vary in different countries where different medical funding models apply. In some countries where health is mandated both by state and federal/central government, there may be significant variation among states and different payers. Concomitant with the challenges of reimbursement, extensive physician and surgeon education has to be conducted to better understand the indication, technique of delivery, mechanism of action, potential side effects and appropriate follow up of the patients. "More is not always better" as outlined by the well-known side effects of off-label use and controversial indication of recombinant Bone Morphogenetic Protein-2 (BMP-2) in spinal fusion. In this respect, cell transplantation and growth factor dosing needs to take into consideration the demanding disc milieu. Once approved, post-market surveillance and other investigator-initiated studies will form the basis of systematic reviews and meta-analysis that will lead to further fine-tuning of indications and or dose regimes.

7 | INTELLECTUAL PROPERTY AND COMMERCIAL SUPPORT

Intellectual property (IP) is a term that describes creations of the mind, such as inventions; literary and artistic works; designs; and symbols, names, and images used in commerce. It is divided into industrial property and copyrights. IP protection allows the holder to exclude others from interfering with or using the property right in specified ways. The main forms of IP are patents, copyrights, trademarks, and trade secrets. To obtain the grant of a patent, one must file a patent application at a patent office. It is important to file an application as soon as possible because after the filing date, disclosing to the public no longer forms prior art and if a full patent application is granted provides protection for 20 years from the earliest filing date of the application, not from the date that the patent was granted.

The first stage in securing IP is to perform a patent search of databases to find out if a patent has already been filed or granted that is similar to your patent. A great place to start a preliminary patent search is Google patents at https://patents.google.com. Other free patent databases are patent lens https://www.lens.org/lens/bio, DOepatents https://www.osti.gov/doepatents/about.jsp developed by the US Department of Energy (DOE), USPTO (United States Patent and Trademark Office) http://patft.uspto.gov and Espacenet https://worldwide.espacenet.com/advancedSearch?locale=en_EP.

This is important because it is possible to spend considerable funds preparing and filing an application when there is prior art that will prevent a patent, or make the patent very narrow. Those individuals within academic institutions will have a technology transfer office (or equivalent) within their institution who will normally manage this process and provide funding if deemed to have potential. Discussion with the local technology transfer office as soon as inventors feel they have something worth patenting is essential. Most technology transfer offices will have their own experiences of patenting and commercialization who will work with inventors to collect initial patent searches. The knowledge from these searches will help with accentuating both the positive aspects of your invention and the differences that exist over the prior art, leading to a stronger patent application.

The next step is to file for a provisional patent application where the filing date is recorded officially with the assistance of a patent attorney. If inventors fail to submit the full application within 12 months of the provisional patent then this will automatically run out and any protection is lost. While, typically inventors do a search after the filing of the provisional patent application but before the filing of the non-provisional patent application, it is advised to complete this prior to filling the provisional. The reason not everyone chooses to do a patent search first is because of the high cost of hiring a patent attorney. Certainly, recording your invention as quickly as possible and getting an early filing date has its advantages. However, the best course to follow, if funds are available, is doing a patent search first before any patent application is filed. By doing a patent search and receiving professional help from a patent attorney you will be able to determine whether it makes sense to move forward and what, if any, rights could be possibly obtained. Furthermore, inventors will search the database for themselves to be informed of the patent landscape so that they can determine whether it even makes sense to start or continue a project in a certain way and whether there may be some available space that they could target.

Do not disclose your inventions until the provisional patent application is on file as any public activity associated with the invention such as telling others at conferences, in abstracts or as a publication...
negatively affects the patenting. This creates a conflict with academia in terms of putting students on a patentable project. After all, many academics are going to need assistance from students in order to bring their invention into being. However, students need publications, presentations, abstracts, etc. for their career, which are often delayed by the patenting process.

Some governmental or private funding is only accessible once you have a patent application on file. Typically, the research projects proposed should not only be beneficial to health but also have a strong focus on knowledge translation with clear milestones and decision points. This is also a Catch-22, that is, easier to get funding with a patent, but need data for the patent, data is usually only possible with funding. Furthermore, once the patent is filed the clock is ticking as the patent is only enforceable for a limited time. This, particularly for clinical therapies, means that protected time can run out before products reach the clinic.

A consideration of where to protect IP is also important, there are many factors to consider before selecting which countries to apply for patent rights. Among the key considerations are the available budget, market opportunities, the time pressure that exist, the location of suppliers and competitors. As a rule of thumb, the most common regions are the United States, Europe, China, Japan, India, Russia, Brazil, South Korea, and Mexico, because they are large economies. Other countries such as Canada, Australia, and South Africa and far eastern economies, such as Thailand and Indonesia, should also be considered. While patent law has been harmonized on an international level, there are still differences between countries. Estimating costs per country per year is challenging. Costs usually have an official, an associate or attorney fee, a translation fee and a maintenance fee in many countries. It is estimated that if one was to obtain a patent in each of the close to 200 countries that exist on the planet the cost would be $2,000,000 for filing, issuance and maintaining the patent for its full term. The best strategy is to first get the US patent on file, then file for a PCT which cost roughly about $5000 and buys you an additional 18 months when you add from the date you file the US patent application before going into other countries or jurisdictions. There are five leading jurisdictions to file patents. The US patent, the European patent office, and the Japan patent office are called the Tri-lateral and they work closely together. Then there are the Chinese and Korean jurisdictions. Thus 90% of patent applications are filed in the Tri-lateral, China, and Korea. However, you have to make sure that you have something that is economically worthwhile before going international.

Financing a commercial operation is a difficult task for many academic IP owners, particularly with the added stress of working at a University. In order to encourage commercialization of intellectual property developed by universities or colleges, some types of support and assistance are available. Where technology transfer offices exist, early conversations are essential to gain university backing and support for patent applications and funding. Furthermore, there are often government resources available and nongovernmental organizations that provide support to technology and innovation entrepreneurs. Gaining support for patenting may require development of a business model at many institutions.

Ideas that are promising can start in universities and evolve into highly profitable businesses. The development of a spin-out from the university is challenging as most academics have no experience in understanding what the customer needs, assessing the demands of the market demand and raising money. Apart from being risky, a spin-out requires time, effort, and funding. For research to be transformed into a successful business, there are five steps namely, research, proof of research market and technology, market and technology development, product and business development and exit. Funding sources depend on what step and can come from government, holding companies, venture capital, customers, industrial partners, banks, angels and crowd funding to mention a few.

Recently, “incubators” have developed in the United States, Europe, and Asia, where an inventor can have support during product development. These incubators are set up and supported by academic institutions, governmental agencies, nonprofit foundations, and even commercial entities with financial support coming from their respective sponsors. Similar to business incubators, these organizations provide not only infrastructure and resources to accelerate business development but to translate the IP towards a commercial product. This is often done in exchange for a share of or exclusive transferrable license rights to the IP. As these incubators or engines can be highly specific to the medical field and hold much specific expertise, they are able to considerably accelerate the formation and maturation of spinouts in a successful manner. At the moment it can take millions of dollars and on average 12 years to get from bench to patients depending on the invention.

8 | DISCUSSION

Over the last two decades, there has been a vast amount of published literature on the preclinical development of novel therapies for IVD degeneration. However, to date we still do not have a therapy which addresses this unmet clinical need. Through scientific research, the IVD field has a greater understanding of the physiological and catabolic environment of the degenerate niche and the biological impact that it has on the cells and extracellular matrix. Research within the community has also uncovered key differences in cell behavior and phenotype with species and culture conditions. It is essential that this scientific knowledge is incorporated into the preclinical design to accelerate and improve translation of findings from preclinical development to clinical studies. It is accepted that the culture conditions used within preliminary proof of concept studies will depend on availability of resources and the research question being investigated. However, at some point during the preclinical phase, novel therapies should be investigated using human cells/tissues within culture conditions that mimic those most closely seen within the degenerate human IVD (Table 1). Utilizing human cells/tissues early within the developmental pipeline will enable aspects such as patient variability to be explored and will require multiple patient samples to be investigated in vitro. These experiments will be the most clinically relevant and thus reduce risk of failure within clinical studies. Standardized approaches to preclinical investigations of novel therapies from 2D culture to organ culture systems, which mimic the in vivo IVD
(Figure 1), will aid comparison with competing therapeutics, so that the best candidate therapies go forward to clinical testing and, thus, improve the chances of progression to clinical use. The therapeutics found to be most promising in the preclinical (in vitro/ex vivo) phase still need to be tested in animals before they can enter human clinical trials. As no single animal model will exactly match human IVD degeneration in all of its complex aspects, it is important to choose an appropriate animal model, based on the most important research questions and desired outcome parameters. Small animal (eg, rodent) models are very useful for fundamental/safety studies, whereas the more expensive large animal models are more suitable for translational/efficiency studies. In all animal models, however, the outcomes should be determined objectively, for example, by randomization, blinding, and quantitative scoring systems.

Scientists are often not well informed about the regulatory pathway. Hence, they should contact their local regulatory authority as early as possible to gain appropriate advice. To determine the pathway, the therapeutic under investigation should be classified which will define the preclinical work required for regulatory acceptance. As work proceeds, it must be fully documented in accordance with GLP procedures and entered in a treatment strategy file so that they can be submitted and reviewed as part of the regulatory process.

To obtain meaningful results from a clinical trial, regardless of its therapeutic success, applying regulatory knowledge, developing a good design and thorough planning, with sufficient control throughout the trial is essential. Investigator brochures, summarizing principal and pertinent preclinical results, are important to inform the clinical trial team. Clinical trial protocols must define IFU with strict and unambiguous inclusion and exclusion criteria to create a focused and uniform patient population. Outcome measures must be well defined and validated across centers and their collection and management must be controlled.

IP is an almost necessary component for bringing new therapeutic agents to the clinic. Without it, commercialization is nearly impossible. Hence researchers should be mindful of IP in their dissemination activities. IP searches need to be performed early and prior to external discussions. Provisional and patent applications can provide protection, but are not without substantial costs, and a business plan should be developed as part of the IP strategy. For this purpose, discussions with the institutional technology transfer office or patent agents should be done early and are immensely helpful. For IP commercialization, licensing to established companies is one option but SMEs are more attractive in terms of retaining control and involvement. For SMEs, valuable developmental resources include governmental valorization grants/loans and incubators/engines.

In conclusion, for successful translation of regenerative therapies to clinic, it is essential to plan your pathway to clinic from the outset, take advice early on regulatory and commercial aspects and consider the required proof of concept experiments required to satisfy regulatory approval for clinical trials. Do not delay too long, otherwise any protection will run out, which makes commercial interest difficult (and often this is the only way to fund expensive clinical trials).

ACKNOWLEDGEMENTS
This work was supported by funding to M.A.T. and K.I. by AOSpine International (SRN2011_11), to M.A.T. by the Dutch Arthritis Foundation (LLP22 & LLP12), to C.L.M. and A.T. by the Medical Research Council (MR/P026796/1) and the Arthritis Research UK (21497).

Conflict of interest
The authors declare no potential conflict of interests.

Authors contribution
All authors contributed to writing and providing critical feedback for this perspective manuscript. A.T. and F.C.B. were responsible for final production. A.D. and K.I. submitted the manuscript.

ORCID
Frances C. Bach http://orcid.org/0000-0002-4481-0051
Marianna A. Tryfonidou http://orcid.org/0000-0002-2333-7162
Christine L. Le Maitre http://orcid.org/0000-0003-4489-7107
Ashish D. Diwan http://orcid.org/0000-0003-1037-8421
Keita Ito http://orcid.org/0000-0002-7372-4072

REFERENCES
1. Bridgelal Ram M, Grocott PR, Weir HC. Issues and challenges of involving patients in medical device development. Health Expect. 2008; 11:63-71.
2. European Medicine Agency. Good laboratory practice compliance. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000158.jsp. Accessed April 16, 2018.
3. Le Maitre CL, Hoyland JA, Freemont AJ. Studies of human intervertebral disc cell function in a constrained in vitro tissue culture system. Spine (Phila Pa 1976). 2004;29:1187-1195.
4. Paul CP, Zuiderbaan HA, Zandieh Doulabi B, et al. Simulated-physiological loading conditions preserve biological and mechanical properties of caprine lumbar intervertebral disks in ex vivo culture. PLoS One. 2012;7:e33147.
5. van Dijk B, Potier E, van Dijk M, Langelaan M, Papen-Botterhuis N, Ito K. Reduced toxicity stimulates an inflammatory response in nucleus pulposus tissue that can be limited by a COX-2-specific inhibitor. J Orthop Res. 2015;33:1724-1731.
6. Grant M, Epure LM, Salem O, et al. Development of a large animal long-term intervertebral disc organ culture model that includes the bony vertebrae for ex vivo studies. Tissue Eng Part C Methods. 2016; 22:636-643.
7. Rosenzweig DH, Tremblay Gravel J, Bisson D, et al. Comparative analysis in continuous expansion of bovine and human primary nucleus pulposus cells for tissue repair applications. Eur Cell Mater. 2017;33:240-251.
8. Bach FC, Laagland LT, Grant MP, et al. Link-N: the missing link towards intervertebral disc repair is species-specific. PLoS One. 2017; 12:e0187831.
9. Wang F, Gao ZX, Cai F, et al. Formation, function, and exhaustion of notochordal cytoplasmic vacuoles within intervertebral disc: current understanding and speculation. Oncotarget. 2017;8:57800-57812.
10. Bach FC, de Vries SA, Krouwels A, et al. The species-specific regenerative effects of notochordal cell-conditioned medium on chondrocyte-like cells derived from degenerated human intervertebral discs. Eur Cell Mater. 2015;30:132-147.
11. Pattappa G, Li Z, Peroglio M, Wismier N, Alini M, Grad S. Diversity of intervertebral disc cells: phenotype and function. J Anat. 2012;221: 480-496.
12. Le Maitre CL, Freemont AJ, Hoyland JA. Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration. *Arthritis Res Ther.* 2007; 9:R45.

13. Vo NV, Hartman RA, Patil PR, et al. Molecular mechanisms of biological aging in intervertebral discs. *J Orthop Res.* 2016;34:1289-1306.

14. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther.* 2005;7:R732-R745.

15. Alini M, Eisenstein SM, Ito K, et al. Are animal models useful for studying human disc disorders/degeneration? *Eur Spine J.* 2008; 17:2-19.

16. Kluba T, Niemeyer T, Gaismaier C, Grunder T, et al. An in vitro organ culturing system for intervertebral disc explants: initial characterization and potential use for tissue engineering. *Spine (Phila Pa 1976).* 2005;30:2743-2748.

17. Lee JY, Hall R, Pelinkovic D, et al. New use of a three-dimensional pellet culture system for human intervertebral disc cells: initial characterization and potential use for tissue engineering. *Spine (Phila Pa 1976).* 2001;26:2316-2322.

18. Colombini A, Lopa S, Ceriani C, et al. In vitro characterization and in vivo behavior of human nucleus pulposus and annulus fibrosus cells in clinical-grade fibrin and collagen-enriched fibrin gels. *Tissue Eng Part A.* 2015;21:793-802.

19. Chen JW, Li B, Yang YH, Jiang SD, Jiang LS. Significance of hypoxia in the physiological function of intervertebral disc cells. *Crit Rev Eukaryot Gene Expr.* 2014;24:193-204.

20. Soukane DM, Shirazi-Adl A, Urban JP. Analysis of nonlinear coupled diffusion of oxygen and lactate in intervertebral discs. *J Biomech Eng.* 2005;127:1121-1126.

21. Mokkbi Soukane D, Shirazi-Adl A, Urban JP. Investigation of solute concentrations in a 3D model of intervertebral disc. *Eur Spine J.* 2009;18:254-262.

22. Kraemer J, Kolditz D, Gwinn R. Water and electrolyte content of human intervertebral discs under variable load. *Spine (Phila Pa 1976).* 1985;10:69-71.

23. Li H, Liang C, Tao Y, et al. Acidic pH conditions mimicking degenerative intervertebral disc conditions impair the survival and biological behavior of human adipose-derived mesenchymal stem cells. *Exp Biol Med (Maywood).* 2012;237:945-852.

24. Kitano T, Zerwekh JE, Usui Y, Edwards ML, Flicker PL, Mooney V. Human anulus fibrosis cells overexpressing BMP-7 or BMP-10 in a rabbit disc organ culture model. *Spine (Phila Pa 1976).* 2008;33:831-838.

25. Gantenbein B, Grunder T, Lee CR, et al. In vitro study investigating the survival and phenotype of mesenchymal stem cells following injection into nucleus pulposus tissue. *Arthritis Res Ther.* 2009;11:R20.

26. Arkesteyn ITM, Patier E, Ito K. The regenerative potential of notochordal cells in a nucleus pulposus explant. *Global Spine J.* 2017;7:14-20.

27. Thorpe AA, Dougill G, Vickers L, et al. Thermally triggered hydrogel injection into bovine intervertebral disc tissue explants induces differentiation of mesenchymal stem cells and restores mechanical function. *Acta Biomater.* 2017;54:212-226.

28. Walter BA, Illien-Junger S, Nasser PR, Hecht AC, Iatridis JC. Development and validation of a bioreactor system for dynamic loading and mechanical characterization of whole human intervertebral discs in organ culture. *J Biomech.* 2014;47:2095-2101.

29. Gawri R, Mwale F, Ouelt JD, et al. Development of an organ culture system for long-term survival of the intact human intervertebral disc. *Spine (Phila Pa 1976).* 2011;36:1835-1842.

30. Parolin M, Gawri R, Mwale F, et al. Development of a whole disc organ culture system to study human intervertebral disc. *Evid Based Spine Care J.* 2010;1:67-68.

31. Gantenbein B, Illien-Junger S, Chan SC, et al. Organ culture bioreactors-platforms to study human intervertebral disc degeneration and regenerative therapy. *Curr Stem Cell Res Ther.* 2015;10:339-352.

32. Peroglio M, Gaspar D, Zeugolis DI, Alini M. Relevance of bioreactors and whole tissue cultures for the translation of new therapies to humans. *J Orthop Res.* 2018;36(1):10-21.

33. Sakai D, Andersson GB. Stem cell therapy for intervertebral disc regeneration: obstacles and solutions. *Nat Rev Rheumatol.* 2015;11:243-256.

34. Selard E, Shirazi-Adl A, Urban JP. Finite element study of nutrient diffusion in the human intervertebral disc. *Spine (Phila Pa 1976).* 2003;28:1945-1953.

35. Pei M. Environmental preconditioning rejuvenates adult stem cells' proliferation and chondrogenic potential. *Biomaterials.* 2017;117:10-23.

36. Krouweels A, Melchels FPM, van Rijmen MHP, et al. Comparing hydrogels for human nucleus pulposus cell regeneration: role of osmolarity during expansion. *Tissue Eng Part C Methods.* 2018;24(4):222-232.

37. Bibby SR, Jones DA, Ripley RM, Urban JP. Metabolism of the intervertebral disc: effects of low levels of oxygen, glucose, and pH on rates of energy metabolism of bovine nucleus pulposus cells. *Spine (Phila Pa 1976).* 2005;30:487-496.

38. Le Maitre CL, Binch AL, Thorpe AA, Hughes SP. Degeneration of the intervertebral disc with new approaches for treating low back pain. *J Neurosurg Sci.* 2015;59:47-61.

39. Sakai D, Schol J. Cell therapy for intervertebral disc repair: clinical perspective. *J Orthop Transl.* 2017;9:8-18.

40. Roberts S, Menege J, Sivan S, Urban JP. Bovine explant model of degeneration of the intervertebral disc. *BMC Musculoskelet Disord.* 2008;9:24.

41. Korecki CL, Costi JJ, Iatridis JC. Needle puncture injury affects intervertebral disc mechanics and biology in an organ culture model. *Spine (Phila Pa 1976).* 2006;31:1808-1809.

42. van Dijk BJG, Potier E, Ito K, et al. Thermally triggered hydrogel injection into bovine nucleus pulposus explants for evaluating regenerative therapies. *Ann Biomed Eng.* 2016;44:44:1798-1807.

43. van Dijk BJG, Potier E, Ito K. Long-term culture of bovine nucleus pulposus explants in a native environment. *Spine J.* 2013;13:454-463.

44. van Dijk B, Potier E, Ito K. Culturing bovine nucleus pulposus explants by balancing medium osmolarity. *Tissue Eng Part C Methods.* 2011;17:1089-1096.

45. Gantenbein B, Grunder T, Lee CR, et al. An in vitro organ culturing system for intervertebral disc explants with vertebral endplates: a feasibility study with ovine caudal discs. *Spine (Phila Pa 1976).* 2006;31:2665-2673.

46. van Dijk B, Potier E, Licht R, Creemers L, Ito K. The effect of a cyclooxygenase 2 inhibitor on early degenerated human nucleus pulposus explants. *Global Spine J.* 2014;4:33-40.

47. van Dijk BGM, Potier E, van Dijk M, Creemers LB, Ito K. Osteogenic protein 1 does not stimulate a regenerative effect in cultured human degenerated nucleus pulposus tissue. *J Tissue Eng Regen Med.* 2017;11:2127-2135.
THORPE ET AL.

55. Schmidt H, Galbusera F, Rohlmann A, Shirazi-Adil A. What have we learned from finite element model studies of lumbar intervertebral discs in the past four decades? J Biomech. 2013;46:2342-2355.

56. Viceconti M, Henneey A, Morley-Fletcher E. In silico clinical trials: how computer simulation will transform the biomedical industry. Int J Clin Trials. 2016;3(2):37-46.

57. Le Maître CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans. 2007;35:652-655.

58. Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine (Phila Pa 1976). 2004;29:2691-2699.

59. Brinjikji W, Diehn FE, Jarvik JG, et al. MRI findings of disc degeneration are more prevalent in adults with low back pain than in asymptomatic controls: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2015;36:2394-2399.

60. Brinjikji W, Lueter PH, Comstock B, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol. 2015;36:811-816.

61. Pye SR, Reid DM, Smith R, et al. Radiographic features of lumbar disc degeneration and self-reported back pain. J Rheumatol. 2004;31:753-758.

62. Adams MA. Biomechanics of back pain. Spine (Phila Pa 1976). 2008;33:1305-1312.

63. Mei J, Bergknut N. Degenerative lumbar sacral stenosis in dogs. Vet Clin North Am Small Anim Pract. 2010;40:983-1009.

64. Tellegen AR, Willems N, Beukers M, et al. Intradiscal application of a recombinant human osteogenic protein-1 restores the viscoelastic properties of degenerated intervertebral discs. Spine J. 2006;6:692-703.

65. Imai Y, Okuma M, An HS, et al. Restoration of disc height loss by recombinant human osteogenic protein-1 injection into intervertebral discs undergoing degeneration induced by an intradiscal injection of chondroitinase ABC. Spine (Phila Pa 1976). 2007;32:1197-1205.

66. Wuile AR, Willems N, Kamada H, et al. Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976). 2005;30:25-32.

67. Chou T, An HS, Akiyama Y, et al. Effects of growth differentiation factor-5 on the intervertebral disc—in vitro bovine study and in vivo rabbit disc degeneration model study. Spine (Phila Pa 1976). 2006;31:2909-2917.

68. Tellegen AR, Willems N, Beukers M, et al. Intradiscal application of a PCLA-PEG-PCLA hydrogel loaded with celecoxib for the treatment of back pain in canines: What’s it for in humans? J Tissue Eng Regen Med. 2017;12(3):642-652.

69. Bowden AE, Stolworthy DK, Fullwood RA, Bridgewater LC. Biomechanical analysis of the camellid cervical intervertebral disc. J Orthopaedic Translation. 2015;3(1):34-43.

70. Bowden AE, Stolworthy DK, Fullwood RA, Bridgewater LC. Mechanical parallels for a camellid cervical spine model of lumbar disc degeneration. Conference Paper presented at: 2nd International Spine Research Symposium, 2013; Philadelphia, PA.

71. Bergknut N, Smolders LA, Grinwis GC, et al. Intervertebral disc degeneration in the dog. Part 1: anatomy and physiology of the intervertebral disc and characteristics of intervertebral disc degeneration. Vet J. 2013;195:282-291.

72. Chan D, Song Y, Sham P, Cheung KM. Genetics of disc degeneration. Eur Spine J. 2006;15(suppl 3):S317-S325.

73. Feng Y, Egan B, Wang J. Genetic factors in intervertebral disc degeneration. Genes Dis. 2016;3:178-185.

74. Kamper M, Hamann N, Prein C, et al. Early changes in morphology, bone mineral density and matrix composition of vertebral lead to disc degeneration in aged collagen IX−/− mice. Matrix Biol. 2016;49:132-143.

75. Zhang Y, Xiong C, Kudielka M, et al. Early onset of disc degeneration in SM/J mice is associated with changes in ion transport systems and fibrotic events. Matrix Biol. 2018. https://doi.org/10.1016/j.matbio.2018.03.024.

76. Choi H, Tessler S, Silagi ES, et al. A novel mouse model of intervertebral disc degeneration shows altered cell fate and matrix homeostasis. Matrix Biol. 2018. https://doi.org/10.1016/j.matbio.2018.03.019.

77. Bach FC, Zhang Y, Miranda-Bedate A, et al. Increased caveolin-1 in intervertebral disc degeneration facilitates repair. Arthritis Res Ther. 2016;18:59.

78. Brown EA, Dickinson PJ, Mansour T, et al. FGF4 retrogene on CFA12 is responsible for chondrodystrophy and intervertebral disc disease in dogs. Proc Natl Acad Sci U S A. 2017;114:11476-11481.

79. Mao HJ, Chen QX, Han B, et al. The effect of injection volume on disc degeneration in a rat tail model. Spine (Phila Pa 1976). 2011;36:E1062-E1069.

80. Carragee EJ, Don AS, Hurwitz EL, Cuellar JM, Carroll J, Herzog R. 2009 ISSLS prize winner: does discography cause accelerated progression of degeneration changes in the lumbar disc: a ten-year matched cohort study. Spine (Phila Pa 1976). 2009;34:2338-2345.

81. Matta A, Karim MZ, Isemann DE, Erwin WM. Molecular therapy for degenerative disc disease: clues from secretome analysis of the notochordal cell-rich nucleus pulposus. Sci Rep. 2017;7:45623.
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf. Accessed XX X, XX.

138. LiArm S, Khayatzadeh S, Hamilton D, Bini S, Chahine N. Outcome measures in orthopaedic research of the joints and spine. Scientific Workshop at the Proceedings of the Annual Scientific Meeting of the Orthopaedic Research Society, New Orleans, USA, 2018.

139. Samartzis D, Borthakur A, Belfer I, et al. Novel diagnostic and prognostic methods for disc degeneration and low back pain. Spine J. 2015;15:1919-1932.

140. Noriega DC, Ardura F, Hernandez-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2017;101:1945-1951.

141. Kumar H, Ha DH, Lee EJ, et al. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther. 2017;8:262.

142. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells. 2015;33:146-156.

143. Yin W, Pauza K, Olan WJ, Doerzbacher JF, Thorne KJ. Intradiscal injection of fibrin sealant for the treatment of symptomatic lumbar internal disc disruption: results of a prospective multicenter pilot study with 24-month follow-up. Pain Med. 2014;15:16-31.

144. Kallewaard JW, Geurts JW, Kessels A, Willems P, van Santbrink H, van Kleef M. Efficacy, safety, and predictors of intradiscal methylgene blue injection for discogenic low back pain: results of a multicenter prospective clinical series. Pain Pract. 2016;16:405-412.

145. Geurts JW, Kallewaard JW, Kessels A, et al. Efficacy and cost-effectiveness of intradiscal methylene blue injection for chronic discogenic low back pain: study protocol for a randomized controlled trial. Trials. 2015;16:532.

146. Peng B, Pang X, Wu Y, Zhao C, Song X. A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. Pain. 2010;149:124-129.

147. Levi DS, Horn S, Walko E. Intradiscal methylene blue treatment for diskogenic low back pain. PM R. 2014;6:1030-1037.

148. Sainoh T, Inage K, Orita S, et al. Correlation among inflammatory cytokine expression levels, degree of disk degeneration, and predominant clinical symptoms in patients with degenerated intervertebral discs. Asian Spine J. 2017;11:472-477.

149. Monfett M, Harrison J, Boachie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update. Int Orthop. 2016;40:1321-1328.

150. Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. Lumbar intradiscal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study. PM R. 2016;8:1-10.

151. Levi D, Horn S, Tyszko S, Levin J, Hecht-Leavitt C, Walko E. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: preliminary results from a prospective trial. Pain Med. 2016;17:1010-1022.

152. Akeda K, Ohishi K, Masuda K, et al. Intradiscal injection of autologous platelet-rich plasma releasate to treat discogenic low back pain: a preliminary clinical trial. Asian Spine J. 2017;11:380-389.

153. Nguyen C, Boutron I, Baron G, et al. Intradiscal glucocorticoid injection for patients with chronic low back pain associated with active discopathy: a randomized trial. Ann Intern Med. 2017;166:547-556.

154. Kannan A, Dodwad SN, Hsu WK. Biologics in spine arthrodesis. J Spinal Disord Tech. 2015;28:163-170.

155. Voss T, Paranjpe AS, Cook TG, Garrison NDW. A short introduction to intellectual property rights. Tech Vasc Interv Radiol. 2017;20:116-120.

156. Sternitzke C. Drug repurposing and the prior art patents of competitors. Drug Discov Today. 2014;19:1841-1847.

157. Garcia AM, Lopez-Moya JR, Ramos P. Key points in biotechnological patents to be exploited. Recent Pat Biotechnol. 2013;7:94-97.

158. Santer V. Search patents outside U.S. Biotechnology. 1994;12:552.

How to cite this article: Thorpe AA, Bach FC, Tryfonidou MA, et al. Leaping the hurdles in developing regenerative treatments for the intervertebral disc from preclinical to clinical. JOR Spine. 2018;1:e1027. https://doi.org/10.1002/jsp2.1027